Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
A biopharmaceutical company developing therapies for liver diseases, including NASH.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to stop liver failure in NASH patients Results expected Dec 2026 (estimated) May already have reported ↗
- New pill shows promise for fatty liver in major trial Results expected Mar 2027 (estimated) May already have reported ↗
-
New drug targets fatty liver in transplant patients
Disease control Recruiting nowThis study tests whether resmetirom, a daily pill, can reduce liver fat in people who have had a liver transplant and developed MASH (a type of fatty liver disease). About 120 participants will be randomly assigned to receive either resmetirom or a placebo for 28 weeks. The main …
Phase 2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New registry tracks rezdiffra safety for moms and babies
Knowledge-focused Recruiting nowThis study tracks the safety of the liver drug Rezdiffra (resmetirom) in women with NASH who take it while pregnant or breastfeeding. Researchers will follow about 10 women and their infants up to 12 months old to check for birth defects, growth problems, and other health issues.…
Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC